Clinical Investigation

Kidney International (1990) 37, 980–990; doi:10.1038/ki.1990.74

Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels

Alexander Kagan1, Yaacov Bar-Khayim1, Zehava Schafer1 and Menahem Fainaru1

1Lipid Research Laboratory, Department of Medicine 'A', and Division of Nephrology, Kaplan Hospital, Rehovot, Israel

Correspondence: M Fainaru MD, Beilinson Medical Center, Petah-Tiqva, 49100, Israel.

Received 7 March 1989; Revised 24 July 1989; Accepted 22 September 1989.

Top

Abstract

Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. We quantified the plasma levels and peritoneal loss of lipids and lipoproteins, and studied the composition of plasma and effluent lipoproteins in 16 patients on CAPD (5 females and 11 males, 18 to 76 years old). Five patients were studied prospectively (at 0, 1, 3 and 6 months) and 11 patients at 6 to 58 months on CAPD (N = 30). Elevated levels of plasma VLDL and reduced levels of plasma HDL were maintained in these patients throughout 58 months of CAPD, whereas the initially increased LDL levels showed a tendency towards normalization. All plasma lipoproteins (VLDL, IDL, LDL and HDL) were present in the peritoneal effluent. The lipoproteins isolated from plasma and peritoneal fluid shared a similar lipid and apolipoprotein composition. The peritoneal transport characteristics of plasma lipoproteins were similar to other plasma macromolecules. Their clearance correlated with their molecular mass, plasma concentration and dwell time, but was not affected by duration of CAPD treatment. The plasma lipid and lipoprotein levels were unaffected by the rate of glucose absorption. The peritoneal protein clearance correlated positively with plasma levels of triglyceride and LDL, and negatively with plasma HDL. An inverse correlation was observed also between plasma levels of HDL and its peritoneal clearance (r = -0.393, P < 0.025, N = 30). The continuous peritoneal loss of HDL and the hypertriglyceridemia were found to contribute most to the persistent low plasma levels of HDL in CAPD patients, and thus may lead to the accelerated atherosclerosis observed in these patients.

Top

References

  1. Gokal R, King J, Bogle S, Marsh F, Oliver D, Jakubowski C, Hunt L, Baillod R, Ogg C, Ward M, Wilkinson R: Outcome in patients on continuous ambulatory peritoneal dialysis and hemodialysis: 4-year analysis of a prospective multicentre study. Lancet 1:1105–1109, 1987
  2. Lowering blood cholesterol to prevent heart disease (Consensus Conference). JAMA 253:2080–2086, 1985
  3. National Heart, Lung and Blood Institute: Report of the National Cholesterol Education Program: Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol Levels in Adults. Arch Intern Med 148:36–69, 1988
  4. Goldstein JL, Brown MS: Regulation of low-density lipoprotein receptors: Implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 76:504–507, 1987
  5. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler AH: for the Lipid Research Clinics Program: High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The lipid research clinics coronary primary prevention trial. Circulation 74:1217–1225, 1986
  6. Norbeck HE: Lipid abnormalities in continuous ambulatory peritoneal dialysis patients, in CAPD Prococeedings International Symposium, edited by Legrain M, Paris, Excerpta Medica, 1979, pp. 298–301
  7. Khanna R, Breckenridge C, Roncari D, Digenis G, Oreopoulos DG: Lipid abnormalities in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Bull 3 (suppl):S13–S15, 1983
  8. Cattran DC: The significance of lipid abnormalities in patients receiving dialysis therapy. Perit Dial Bull 3 (suppl):S29–S32, 1983
  9. Oreopoulos DG, Khanna R, Williams P, Vas SI: Continuous ambulatory peritoneal dialysis—1981. Nephron 30:293–303, 1982
  10. Ramos JM, Heaton A, McGurk JG, Ward MK, Kerr DNS: Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 35:20–23, 1983
  11. Lindholm B, Alvestrand A, Norbeck HE, Tranaeus A, Bergstrom J: Long-term metobolic consequences of continuous ambulatory peritoneal dialysis, in Nephrology (vol 2) edited by Robinson RR, New York, Springer-Verlag, 1984, pp. 1611–1626
  12. Loschiavo C, Ferrari S, Panebianco R, Bedogna V, Oldrizzi L, Bonazzi L, Maschio G: Effect of protein-restricted diet on serum lipids and atherosclerosis risk factors in patients with chronic renal failure. Clin Nephrol 29:113–118, 1988
  13. Rubies-Prat J, Espinel E, Joven J, Ras MR, Pira L: High-density lipoprotein cholesterol subfractions in chronic uremia. Am J Kidney Dis 9:60–65, 1987 | PubMed |
  14. Bagdade JD, Albers JJ: Plasma high-density lipoprotein concentration in chronic-hemodialysis and renal-transplant patients. N Engl J Med 296:1436–1439, 1977 | PubMed | ISI | ChemPort |
  15. Chan MK, Chuah P, Raftery MJ, Baillod RA, Sweny P, Varghese Z, Moorhead JF: Three years' experience of continuous ambulatory peritoneal dialysis. Lancet (ii): 1409–1412, 1981
  16. Lindholm B, Bergstrom J, Norbeck HE: Lipoprotein metabolism in patients on continuous ambulatory peritoneal dialysis, in Advances in Peritoneal Dialysis, edited by Gahl GM, Kessel M, Nolph KD, Amsterdam, Excerpta Medica, 1981 pp. 434–436
  17. Cantaluppi A, Scalamogna A, Guerra L, Graziani G, Ponticelli C: Plasma lipid and lipoprotein levels in patients treated with CAPD. Perit Dial Bull 2:99, 1982
  18. Triolo G, Boggio-Bertinet D, Salomone M, Segoloni GP, Vercellone A: Changes in serum lipids with prolonged CAPD. Perit Dial Bull 2:192–193, 1982
  19. Kurtz SB, Wong VH, Anderson CF, Vogel JP, McCarthy JT, Mitchell III JC, Kumar R, Johnson WJ: Continuous ambulatory peritoneal dialysis. Three years' experience at the Mayo Clinic. Mayo Clin Proc 58:633–639, 1983
  20. Rubin J, Walsh D, Bower JD: Diabetes, dialysate losses, and serum lipids during continuous ambulatory peritoneal dialysis. Am J Kidney Dis 10:104–108, 1987
  21. Boeschoten EW, Zuyderhoudt FMJ, Krediet RT, Arisz L: Changes in weight and lipid concentrations during CAPD treatment. Perit Dial Int 8:19–24, 1988 | ISI |
  22. Nolph KD, Popovich RP, Moncrief JW: Theoretical and practical implications of continuous ambulatory peritoneal dialysis. Nephron 21:117–122, 1978
  23. Khanna R, Nolph KD: Peritoneal morphology and microcirculation, in Continuous Ambulatory Peritoneal Dialysis, edited by Gokal R, Edinburgh, Churchill Livingstone, 1986, pp. 14–17
  24. Heuck CC, Ritz E: Hyperlipoproteinemia in renal insufficiency. Nephron 25:1–7, 1980
  25. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 19:625–637, 1981 | PubMed | ISI | ChemPort |
  26. Golper TA: Therapy for uremic hyperlipidemia. Nephron 38:217–225, 1984
  27. Frederickson DS, Levy RI, Lees RS: Fat transport in lipoproteins: An integrated approach to mechanisms and disorders. N Engl J Med 276:34–44, 94–103, 215–225, 273–281, 1967
  28. Chan MK, Varghese Z, Persaud JW, Baillod RA, Moorhead JF: Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: The relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 17:183–190, 1982 | PubMed | ISI | ChemPort |
  29. Sniderman A, Cianflone K, Hutchinson T, Barre P, Kwiterovich P, Prichard S: Increased prevalence of hyperapo-betalipoproteinemia in patients treated with continuous ambulatory peritoneal dialysis. (abstract) Perit Dial Bull 6 (suppl):S20, 1986
  30. Fein PA, Antignani A, Mushnick R, Jorden A, Goldwasser P, Mittman N, Avram MM: Lipids and PTH in diabetic and nondiabetic uremic patients on CAPD. A prospective role for higher HDL. (abstract) Perit Dial Int 8:78, 1988
  31. Conteras NEIR, Camejo G, Lopez F, Aveledo L, Bellorin-Font E, Amair P, Boissiere M, Paz-Martinez V, Weisinger JR: The lipid abnormalities observed in patients on CAPD are not related to the glucose intolerance or insulin resistance. (abstract) Perit Dial Bull 7 (suppl):S18, 1987
  32. Dulaney JT, Hatch FE Jr: Peritoneal dialysis and loss of proteins: A review. Kidney Int 26:253–262, 1984 | PubMed | ISI | ChemPort |
  33. Hain H, Kessel M: Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transplant 2:67–72, 1987
  34. Berlyne GM, Hewitt V, Jones JH, Nilwarangkur S: Protein loss in peritoneal dialysis. Lancet i:738–741, 1964
  35. Breckenridge WC, Roncari DAK, Khanna R, Oreopoulos DG: The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. Atherosclerosis 45:249–258, 1982 | Article | PubMed | ChemPort |
  36. Saku K, Sasaki J, Naito S, Arkawa K: Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 51:220–224, 1989 | PubMed | ChemPort |
  37. Querfeld U, LeBouef RC, Salusky IB, Fine RN: Lipoproteins in pediatric patients treated with CAPD/CCPD. (abstract) Kidney Int 33:248, 1988
  38. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during continuous ambulatory peritoneal dialysis (CAPD): I. Different characteristics for peritoneal loss of low and high molecular weight proteins. Kidney Int 37:971–979, 1990 | Article | PubMed | ISI | ChemPort |
  39. Havel RJ, Eder HA, Bragdon JH: Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353, 1955 | PubMed | ISI | ChemPort |
  40. Lipid Research Clinics Manual of Laboratory Operations. Lipid and lipoprotein analysis, DHEW Publ No. (NIH) 75, 628, May 1974
  41. Bachorik PS, Walker RE, Virgil DG: High density lipoprotein cholesterol in heparin-MnCl2 supernates determined with the Dow enzymic method after precipitation of Mn2+ with HCO3-. Clin Chem 30:839–842, 1984
  42. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475, 1974 | PubMed | ISI | ChemPort |
  43. Bucolo G, David H: Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19:476–482, 1973 | PubMed | ISI | ChemPort |
  44. Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem 234:466–468, 1959 | PubMed | ISI | ChemPort |
  45. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509, 1957 | PubMed | ISI | ChemPort |
  46. Chiamori N, Henry RJ: Study of the ferric chloride method for determination of total cholesterol and cholesterol esters. Am J Clin Pathol 31:305–309, 1959
  47. Deckelbaum RJ, Olivecrona T, Fainaru M: The role of different albumin preparations on production of human plasma lipoprotein-like particles in vitro. J Lipid Res 21:425–434, 1980
  48. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275, 1951 | PubMed | ISI | ChemPort |
  49. Fainaru M, Mahley RW, Hamilton RL, Innerarity TL: Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia. J Lipid Res 23:702–714, 1982
  50. Fainaru M, Deckelbaum R, Golbus MS: Apolipoproteins in human fetal blood and amniotic fluid in mid-trimester pregnancy. Prenatal Diagn 1:125–129, 1981
  51. Zar JH: Biostatistical Analysis. Englewood Cliff New Jersey, Prentice Hall, Inc., 1974
  52. Friedlander Y, Kark JD, Eisenberg S, Stein Y: Calculation of LDL-cholesterol from total cholesterol, triglyceride and HDL-cholesterol: A comparison of methods in the Jerusalem lipid research clinic prevalence study. IsrJ Med Sci 18:1242–1252, 1982
  53. Leitersdorf E, Gottehrer N, Fainaru M, Friedlander Y, Friedman G, Tzivoni D, Stein Y: Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis 59:75–93, 1986
  54. Shen BW, Scanu AM, Kezdy FJ: Structure of human lipoproteins inferred from compositional analysis. Proc Natl Acad Sci USA 74:837–841, 1977
  55. Courtice FC, Roberts DCK: Peritoneal fluid in the rabbit: Permeability of the mesothelium to proteins, lipoproteins and acid hydrolase. Lymphology 8:1–10, 1975
  56. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of protein loss in CAPD. Implications for a brighter future. (abstract) Perit Dial Bull 7 (suppl):S41, 1987
  57. Nolph KD: Anatomic and physiologic aspects of peritoneal dialysis, in Nephrology (vol 2)(Proc of the 9th Int Congress of Nephrol) edited by Robinson RR, New York, Springer-Verlag, 1984, pp. 1561–1580
  58. Miller FN, Nolph KD, Harris PD, Rubin J, Weigman DL, Joshua IG, Twardowski ZJ, Ghods AJ: Microvascular and clinical effects of altered peritoneal dialysis solutions. Kidney Int 15:630–639, 1979
  59. Wayland H: Action of histamine of the microvasculature, in Proceedings of the 1st International Symposium on CAPD, edited by Legrain M, Amsterdam, Excerpta Medica, 1980, pp. 18–27
  60. Kaysen GA, Schoenfeld PY: Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 25:107–114, 1984 | PubMed | ISI | ChemPort |
  61. Twardowski ZJ, Janicka L, Tarkowska A, Jankowska H: Kinetics of albumin transport in intermittant peritoneal dialysis (IPD) and continuous ambulatory peritoneal dialysis (CAPD). (abstract) Kidney Int 26:604, 1984
  62. Mactier RA, Khanna R, Twardowski Z, Moore H, Nolph KD: Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 80:1311–1316, 1987 | PubMed | ISI | ChemPort |
  63. Giordano C, Capodicasa G, De Santo NG: Artificial gut for total parenteral nutrition through the peritoneal cavity. Int J Artif Organs 3:326–330, 1980
  64. Mitwalli A, Rodela H, Brandes L, Wanless I, Wu G, Ogilvie R, Schilling H, Oreopoulos DG: Is fat absorbed from the peritoneum?. (abstract) Kidney Int 27:183, 1985
  65. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Low level of plasma HDL in CAPD patients may be due to HDL loss into dialysate. (abstract) Perit Dial Int 8:82, 1988
  66. Fainaru M, Kagan A, Bar-Khayim Y, Schafer Z: HDL loss contributes to the low plasma levels in patients treated by continuous ambulatory peritoneal dialysis (CAPD), in Poster sessions, Abstract Book, 8th International Symposium on Atherosclerosis, Roma, CIC Edizioni Internazionali, 1988, p. 235
  67. Bagdade JD, Porte D, Bierman EL: Hypertriglyceridemia: A metabolic consequence of chronic renal failure. N Engl J Med 279:181–185, 1968 | PubMed | ISI | ChemPort |
  68. Grutzmacher P, Marz W, Peschke B, Gross W, Schoeppe W: Lipoproteins and apoproteins during the progression of chronic renal disease. Nephron 50:103–111, 1988
  69. Goldberg A, Sherrard DJ, Brunzell JD: Adipose tissue lipoprotein lipase in chronic hemodialysis: Role in plasma triglyceride metabolism. J Clin Endocrinol Metab 47:1173–1182, 1978 | PubMed | ISI | ChemPort |
  70. Chan MK, Persaud J, Varghese Z, Moorhead JR: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 25:812–818, 1984 | PubMed | ISI | ChemPort |
  71. Murase T, Cattran DC, Rubenstein B, Steiner G: Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 24:1279–1286, 1975
  72. Lutz W: Effect of protein and peptide fractions from the peritoneal dialysate of patients with chronic renal failure on the lipoprotein lipase activity. Acta Med Pol 20:131–141, 1979
  73. Sakurai T, Miki S, Goto T: Studies on sequential changes of lipid metabolism and atherogenecity in long term CAPD patients in Abstracts, 10th International Congress of Nephrology, London, edited by Davison AM, Oxford, The Alden Press, 1987, p. 197
  74. Lindholm B, Karlander SG, Norbeck HE, Bergstrom J: Glucose and lipid metabolism in peritoneal dialysis, in Peritoneal Dialysis, edited by La Greca G, Biasioli S, Ronco C, Milan, Wichtig Editore, 1982, pp. 219–230
  75. Di Maio G, Carozzi S, Nasini G, Lamperi S: Serum lipids pattern in uremic patients after 48 months of CAPD. (abstract) Perit Dial Bull 4(suppl):S18, 1984
  76. Gokal R, Ramos JM, McGurk JG, Ward MK, Kerr DNS: Hyperlipidemia in patients on continuous ambulatory peritoneal dialysis, in Advances in Peritoneal Dialysis, edited by Gahl GM, Kessel M, Nolph KD, Amsterdam, Excerpta Medica, 1981, pp. 430–433
  77. Appel GB, Blum CB, Shu Chien, Kunis CL, Appel AS: The hyperlipidemia of the nephrotic syndrome (Relation to plasma albumin concentration, oncotic pressure and viscosity). N Engl J Med 312:1544–1548, 1985 | PubMed | ISI | ChemPort |
  78. Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: Effects on lipoprotein metabolism. Kidney Int 33:1160–1168, 1988 | PubMed | ISI | ChemPort |
  79. Tranaeus A, Heimburger O, Lindholm B, Bergstrom J: Six years' experience of CAPD at one centre: a survey of major findings. Perit Dial Int 8:31–41, 1988
  80. Blum CB, Levy RI, Eisenberg S, Hall III M, Goebel RH, Berman M: High density lipoprotein metabolism in man. J Clin Invest 60:795–807, 1977
  81. Lindholm B, Bergstrom J: Nutritional aspects of CAPD, in Continuous Ambulatory Peritoneal Dialysis, edited by Gokal R, London, Churchill Livingstone, 1986, pp. 228–264
  82. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end stage renal disease (Difference between treatment by hemodialysis or peritoneal dialysis). J Clin Invest 77:1071–1083, 1986 | PubMed | ISI | ChemPort |
  83. Roncari DAK, Beckenridge WC, Khanna R: Rise in high density lipoprotein cholesterol in some patients treated with CAPD. Perit Dial Bull 1:136–137, 1981
  84. Wessel-Aas T, Blomhoff JP, Wideroe TE, Wirum E, Nilsen T: The effect of systemic heparinization on plasma lipoproteins and toxicity in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 216:85–92, 1984
  85. Durrington PN: High-density lipoprotein cholesterol: Methods and clinical significance. CRC Critical Rev Clin Lab Sci 18:31–78, 1983
  86. Rachmilewitz D, Albers JJ, Saunders DR, Fainaru M: Apoprotein synthesis by human duodenojejunal mucosa. Gastroenterology 75:677–682, 1978
  87. Pottenger LA, Getz GS: Serum lipoprotein accumulation in the livers of orotic acid-fed rats. J Lipid Res 12:450, 1971
  88. Wills MR: Uremic toxins and their effect on intermediary metabolism. Clin Chem 31:5–13, 1985
  89. Saku K, Mendoza SG, Laver M, Hynd BA, Gartside PS, Kashyap ML: High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Nephron 50:112–115, 1988 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT